A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2004
12/29/2004	WO2004113303A1 INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF
12/29/2004	WO2004113302A1 N-substituted 6,8-dialkoxy-1,2,3,4-tetrahydro-1h-isoquinoline as potassium channels modulators
12/29/2004	WO2004113301A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/29/2004	WO2004113300A1 Novel tricyclic heterocycle compound
12/29/2004	WO2004113280A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/29/2004	WO2004112821A1 Remedies for diseases with hypermyotonia
12/29/2004	WO2004112811A1 Eye-rinse solution made of grape juice
12/29/2004	WO2004112806A1 Composition for treating or preventing neural disorders
12/29/2004	WO2004112797A1 Hormone replacement- and depression therapy comprising dienogest
12/29/2004	WO2004112787A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/29/2004	WO2004112786A2 Gaboxadol for treating depression and other affective disorders
12/29/2004	WO2004112771A1 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
12/29/2004	WO2004112769A1 Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
12/29/2004	WO2004112762A2 Pharmaceutical formulations of amyloid inhibiting compounds
12/29/2004	WO2004084932A3 Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
12/29/2004	WO2004001014A3 Osteopontin, oligodendrocytes and myelination
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003045392A8 Use of n-(indolcarbonyl-)piperazine derivatives
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	WO2000061774A3 Bone morphogenic proteins
12/29/2004	EP1491556A1 Humanized immunoglobulins and their production and use
12/29/2004	EP1491537A1 Hydroxymorpholinone derivative and medicinal use thereof
12/29/2004	EP1491533A2 Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors
12/29/2004	EP1491532A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetyloholine receptors
12/29/2004	EP1491531A1 (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
12/29/2004	EP1491236A1 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
12/29/2004	EP1491213A1 C-jun phosphorylation inhibitors
12/29/2004	EP1491212A1 Remedy for sleep disturbance
12/29/2004	EP1491211A1 Remedy for glioblastoma
12/29/2004	EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions
12/29/2004	EP1491207A1 Novel screening method
12/29/2004	EP1491205A1 Remedy for hypermyotonia
12/29/2004	EP1491204A1 Process for producing fat composition containing hydrophobic components of glycyrrhiza
12/29/2004	EP1491196A2 Method for treatment of CNS-involved lysosomal storage diseases
12/29/2004	EP1491194A1 Vdac regulator
12/29/2004	EP1491183A2 Use of a plant extract of the Rosaceae family
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490696A2 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
12/29/2004	EP1490409A1 Modified saccharides having improved stability in water
12/29/2004	EP1490406A1 Costimulatory molecule and its use
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490401A1 Vegf peptides and their use
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490367A1 Imidazopyridine derivatives as kinase inhibitors
12/29/2004	EP1490366A1 Novel alkoxypyridine-derivatives
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490363A1 Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
12/29/2004	EP1490361A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490353A1 Method for manufacture of sertindole
12/29/2004	EP1490344A2 Anxiolytic agents with reduced sedative and ataxic effects
12/29/2004	EP1490343A1 New aryl imidazoles and related compounds as c5a receptor modulators
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490340A1 Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490338A1 Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
12/29/2004	EP1490335A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/29/2004	EP1490334A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
12/29/2004	EP1490328A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation
12/29/2004	EP1490324A2 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490315A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
12/29/2004	EP1490112A1 Method and agent for producing therapeutically active blood compositions
12/29/2004	EP1490109A2 Egfr ligands and methods of use
12/29/2004	EP1490108A2 Drg11-responsive (dragon) gene family
12/29/2004	EP1490081A1 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
12/29/2004	EP1490076A2 Novel metabolic targets and markers
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490071A2 Theraputic methods and uses of sapogenins and their derivatives
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
12/29/2004	EP1490068A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
12/29/2004	EP1490067A2 Use of tyrosine kinase inhibitors for treating substance use disorders
12/29/2004	EP1490065A1 Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
12/29/2004	EP1490064A1 Substituted pyridinones as modulators of p38 map kinase
12/29/2004	EP1490063A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
12/29/2004	EP1490062A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490061A1 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
12/29/2004	EP1490057A1 Method for treating cognitive disorders
12/29/2004	EP1490056A1 N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
12/29/2004	EP1490050A2 Methods for alzheimer's disease treatment and cognitive enhancement
12/29/2004	EP1490044A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
12/29/2004	EP1490043A2 Spirocyclic amides as cannabinoid receptor modulators
12/29/2004	EP1490037A1 Taste masked veterinary solid compositions
12/29/2004	EP1490036A1 Sustained release formulation of tramadol
12/29/2004	EP1490033A1 No-donating nsaids adsorbed into carrier particles
12/29/2004	EP1489915A1 Treatment and prevention of inflammatory disorders
12/29/2004	EP1311265B1 Pharmaceutical compositions for treating neurological disorders
12/29/2004	EP1284998B1 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
12/29/2004	EP1267931B1 Rhodamine derivatives for photodynamic diagnosis and treatment
12/29/2004	EP1265891B1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/29/2004	EP1257539B1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders
12/29/2004	EP1233769A4 Novel compounds
12/29/2004	EP1206442A4 Substituted chiral allosteric hemoglobin modifiers
12/29/2004	EP1202727B1 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients
12/29/2004	EP1177178B1 Heterocyclically substituted benzimidazoles, the production and application thereof
12/29/2004	EP1171419B1 Biphenyl derivatives as antagonists of the neurokinine-1 receptor
12/29/2004	EP1148059B1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
12/29/2004	EP1135123B1 Use of isatin derivatives as ion channel activating agents

1 ... 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 ... 1833